Results 41 to 50 of about 881 (146)

Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing

open access: yesEMBO Molecular Medicine, 2023
Cell‐free DNA (cfDNA) can be isolated and sequenced from blood and/or urine of cancer patients. Conventional short‐read sequencing lacks deployability and speed and can be biased for short cfDNA fragments.
Ymke van der Pol   +16 more
doaj   +1 more source

Cell-Free DNA Fragmentation Patterns in a Cancer Cell Line

open access: yesDiagnostics, 2022
Unique bits of genetic, biological and pathological information occur in differently sized cell-free DNA (cfDNA) populations. This is a significant discovery, but much of the phenomenon remains to be explored. We investigated cfDNA fragmentation patterns
Vida Ungerer   +3 more
doaj   +1 more source

Epigenetic analysis of cell-free DNA by fragmentomic profiling

open access: yesProceedings of the National Academy of Sciences, 2022
Cell-free DNA (cfDNA) fragmentation patterns contain important molecular information linked to tissues of origin. We explored the possibility of using fragmentation patterns to predict cytosine-phosphate-guanine (CpG) methylation of cfDNA, obviating the use of bisulfite treatment and associated risks of DNA degradation.
Qing Zhou   +21 more
openaire   +2 more sources

At the dawn: cell-free DNA fragmentomics and gene regulation [PDF]

open access: yesBritish Journal of Cancer, 2021
AbstractEpigenetic mechanisms play instrumental roles in gene regulation during embryonic development and disease progression. However, it is challenging to non-invasively monitor the dynamics of epigenomes and related gene regulation at inaccessible human tissues, such as tumours, fetuses and transplanted organs.
openaire   +2 more sources

Profiling disease and tissue-specific epigenetic signatures in cell-free DNA

open access: yesJournal of Laboratory Medicine, 2022
Programmed cell death, accidental cell degradation and active extrusion constantly lead to the release of DNA fragments into human body fluids from virtually all cell and tissue types.
Oberhofer Angela   +3 more
doaj   +1 more source

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

open access: yesMolecular Oncology, 2022
Stage II–IIIA nonsmall cell lung cancer (NSCLC) patients receive adjuvant chemotherapy after surgery as standard‐of‐care treatment, even though only approximately 5.8% of patients will benefit.
Daan C. L. Vessies   +10 more
doaj   +1 more source

Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients

open access: yesEMBO Molecular Medicine, 2021
Glioma‐derived cell‐free DNA (cfDNA) is challenging to detect using liquid biopsy because quantities in body fluids are low. We determined the glioma‐derived DNA fraction in cerebrospinal fluid (CSF), plasma, and urine samples from patients using ...
Florent Mouliere   +20 more
doaj   +1 more source

Home - About - Disclaimer - Privacy